Seer stock stays independent after takeover bids rejected
Published on 10/31/2026 at 01:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSeer remains independent
- Seer's special committee unanimously rejected two unsolicited, non-binding acquisition proposals.
- The company will proceed independently ahead of its third-quarter results scheduled for November 10.
- The committee said the proposals did not reflect Seer's intrinsic value and future prospects.
Seer, Inc. will remain an independent public company after its special committee unanimously rejected two unsolicited, non-binding acquisition proposals following a three-month review. The company announced the decision on Thursday, October 29, according to a Seer release carried by GlobeNewswire.
Two proposals rejected
The Radoff-JEC Group submitted its proposal on July 28 for all outstanding Class A shares at 2.55 US dollars per share in cash plus a contingent value right. Seer Chair and Chief Executive Officer Omid Farokhzad submitted a separate proposal on July 29 at 2.45 US dollars per share in cash plus two contingent value rights.
The special committee said both offers failed to reflect Seer's intrinsic value. Its review also considered other strategic alternatives and possible interest from additional counterparties. The committee said a sale at this time would undervalue the company and its future prospects.
Results set for November 10
Seer's next scheduled corporate milestone is its third-quarter 2026 results announcement on Tuesday, November 10. The investor relations site lists the company as a life sciences business focused on proteomics and identifies its Proteograph technology as a platform using engineered nanoparticles and automated workflows.
Seer's proteomics platform
Seer develops research-use products for deep, unbiased proteomics. Its Proteograph Product Suite combines engineered nanoparticles, automation instruments, consumables and analytical software to support large-scale protein analysis. The company is headquartered in Redwood City, California, and its products are not intended for diagnostic procedures. The materials reviewed describe Seer as a specialized provider in proteomics but do not establish a verified named peer comparison.
Seer company profile
- Company: Seer, Inc.
- ISIN: US81578P1066
- Ticker: SEER
- Primary listing: Nasdaq
- Headquarters: Redwood City, California
- Next results: Third-quarter 2026 results on November 10, 2026
U.S. equities will remain sensitive to corporate updates and scheduled earnings as investors assess the outlook for growth companies on the S&P 500.
Further company developments are available in more news and analyses on Seer stock.
